A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption.

Advanced Search

Michael J Peluso, Lynda Dee, Danielle Campbell, Jeff Taylor, Rebecca Hoh, Rachel L Rutishauser, John Sauceda, Steven G Deeks, Karine Dubé

Author Information

Michael J Peluso: Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Lynda Dee: AIDS Action Baltimore, Baltimore, MD, USA.
Danielle Campbell: amfAR Institute for HIV Cure Research Community Advisory Board, USA.
Jeff Taylor: amfAR Institute for HIV Cure Research Community Advisory Board, USA.
Rebecca Hoh: Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Rachel L Rutishauser: Division of Experimental Medicine, UCSF, San Francisco, CA, USA.
John Sauceda: Center for AIDS Prevention Studies, UCSF, San Francisco, CA, USA.
Steven G Deeks: Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Karine Dubé: UNC Gillings School of Global Public Health, Chapel Hill, NC, USA.

PMID: 32175090

Analytic treatment interruptions (ATIs) are currently the standard for assessing the impact of experimental interventions aimed at inducing sustained antiretroviral therapy (ART)-free remission in trials related to HIV cure. ATIs are associated with substantial risk to both study participants and their sexual partner(s). Two documented HIV transmissions occurring in the context of ATIs have been recently reported, but recommendations for mitigating the risk of such events during ATIs are limited. We outline a practical approach to risk mitigation during ATI studies and describe strategies we are utilising in an upcoming clinical trial that may be applicable to other centres.

HIV HIV cure research HIV remission research analytical treatment interruption

J Infect Dis. 2019 Jul 2;220(Supplement_1):S5-S6 [PMID: 30779842]
Lancet HIV. 2018 Aug;5(8):e438-e447 [PMID: 30025681]
AIDS Behav. 2008 Sep;12(5):713-20 [PMID: 17985229]
J Infect Dis. 2018 Nov 5;218(12):1954-1963 [PMID: 30085241]
J Infect Dis. 2019 Jul 2;220(Supplement_1):S7-S11 [PMID: 31264692]
Lancet HIV. 2019 Apr;6(4):e259-e268 [PMID: 30885693]
Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269 [PMID: 31177363]
N Engl J Med. 2011 Aug 11;365(6):493-505 [PMID: 21767103]
J Infect Dis. 2019 Jul 2;220(Supplement_1):S12-S15 [PMID: 31264689]
AIDS Res Hum Retroviruses. 2018 Jan;34(1):67-79 [PMID: 28562069]
Curr Opin HIV AIDS. 2016 Jan;11(1):109-15 [PMID: 26633642]
J Infect Dis. 2019 Nov 19;: [PMID: 31742347]
J Infect Dis. 2019 Jul 2;220(Supplement_1):S24-S26 [PMID: 31264691]
Lancet. 2019 Jun 15;393(10189):2428-2438 [PMID: 31056293]
Dev World Bioeth. 2013 Aug;13(2):87-94 [PMID: 23725227]
J Infect Dis. 2019 Jul 2;220(Supplement_1):S1-S4 [PMID: 31264687]
AIDS. 2019 Feb 1;33(2):279-284 [PMID: 30325777]
JAMA. 2016 Jul 12;316(2):171-81 [PMID: 27404185]
S Afr Med J. 2010 Jan;100(1):45-8 [PMID: 20429488]
N Engl J Med. 2000 Mar 30;342(13):921-9 [PMID: 10738050]
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101 [PMID: 16123689]

K23 AI134327/NIAID NIH HHS
P30 AI027763/NIAID NIH HHS
P30 MH062246/NIMH NIH HHS
UM1 AI126611/NIAID NIH HHS

Editorial

Enhanced risk of HIV sexual transmission during structured treatment interruption.HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption.Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.Re: Pre-Exposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruption.How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach.Risk of HIV transmission during dental treatment.[Adherence to antiretroviral therapy during HIV infection, a multidisciplinary approach].Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission.A Modern Collaborative Behavior Analytic Approach to Incidental Naming.

Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach.Time to Engage Young People in HIV Cure Research.HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption.Critical considerations for public engagement in stem cell-related research.Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk.Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.HIV Clinical Providers' Awareness, Attitudes, and Willingness to Support Patient Outreach Efforts for HIV Cure-Directed Research in Philadelphia, United States.Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom.Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria.Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.

See all "Cited by" articles

OpenLB
Open Library of Bioscience